

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Dapagliflozin for treating chronic kidney disease (Review of TA775) [ID6411]

Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
Company	General commentators
AstraZeneca (dapagliflozin)	All Wales Therapeutic and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Kidney Care UKKidney Patient Involvement Network	 Board of Community Health Councils in Wales
Kidney Research UK	British National Formulary
National Kidney Federation	Care Quality Commission
Polycystic Kidney Disease Charity	Department of Health - Northern Ireland
South Asian Health Foundation	Healthcare Improvement Scotland
Specialised Healthcare Alliance	Medicines and Healthcare Products Regulatory Agency
Professional groups	National Association of Primary Care
Association of Renal Industries	National Pharmacy Association
Association of Renal Technologists	NHS Alliance
British Association of Urological	NHS Confederation
Nurses	Scottish Medicines Consortium
British Geriatrics Society	Welsh Government
Royal College of General Practitioners	Welsh Health Specialised Services
Royal College of Nursing	Committee
Royal College of Pathologists	
Royal College of Physicians	<u>Comparators</u>
Royal Pharmaceutical Society	Boehringer Ingelheim (empagliflozin)
Royal Society of Medicine	
Society for DGH Nephrologists	Relevant research groups
UK Clinical Pharmacy Association	Centre for Kidney Research and
UK Kidney Association	Innovation
UK Renal Pharmacy Group	Cochrane Kidney and Transplant Group
	Genomics England MDC Olivia at Trials Unit
<u>Others</u>	MRC Clinical Trials Unit
Department of Health and Social CareNHS England	 National Institute for Health & Care Research
	Associated Public Health Groups
	Public Health Wales
	UK Health Security Agency

Provisional stakeholder list for the evaluation of dapagliflozin for treating chronic kidney disease (Review of TA775) [ID6411]



NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.